Impact BioMedical's stock soared over 65% in pre-market trading after announcing amendments to its merger agreement with Dr Ashley's. The companies extended the merger deadline to July 1, 2026. The deal involves issuing nearly 170 million shares. If the pre-market rally holds, Impact BioMedical would hit its highest level since September 2025.